Pregnant cows were successfully hyperimmunized with all four human rotavirus serotypes, resulting in a 100-fold increase in neutralizing milk antibody titers over those of controls. Milk antibodies were isolated batchwise from 1,000 kg of pooled milk for the first 10 lactation days, yielding 10 kg of freeze-dried milk immunoglobulin concentrate consisting of 50% bovine milk immunoglobulin. Milk immunoglobulin concentrate showed neutralizing activities against all four human rotavirus serotypes that were 100 times higher than those in pooled human milk samples and 10 times higher than those in a commercial pooled immunoglobulin preparation from pooled human blood serum. In vitro neutralization tests showed that milk immunoglobulin concentrate had powerful antiviral activity, even against very high doses of infectious rotaviruses. Because the technology of the milk immunoglobulin concentrate ensures that it is innocuous and can be used for oral application, it is proposed that milk immunoglobulin concentrate be used to induce passive immunity to infantile rotavirus gastroenteritis.
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Rotaviruses, which are members of the family Reoviridae (14) , account for about half of the pediatric hospital admissions of children with acute diarrhea in Western Europe and the United States during the winter (7, 15, 19) . Clinically, rotavirus gastroenteritis is characterized by profuse diarrhea, fever, and vomiting, leading to moderate or severe dehydration (5) .
One of the most important problems with rotavirus infections is their prevention. This involves infants in the first year of life. Active immunization offers one approach to this problem (34) , but we decided to investigate the alternative approach of passive immunization.
It has been shown from results of numerous studies in animals (3, 4, 24, 27, 31) that the presence of antibody in the lumen of the small intestine is of major importance for protection against rotavirus diarrhea. Antibodies in serum, however, do not prevent rotavirus infection (18, 20, 30, 36) . Passive immunity may be provided by breast-feeding, but antibody titers are generally low in breast milk (6) , and many infants are no longer breast-fed when they are most susceptible to rotavirus infection. Alternatively, passive immunity may be provided by the artificial feeding of antibodycontaining preparations. In this study we describe the successful immunization of cows with the four human rotavirus serotypes and the isolation of bovine milk immunoglobulin with potent antiviral activity that is suitable for inducing passive immunity to infantile rotavirus gastroenteritis. Immunization with any of the four human rotavirus serotypes increased the neutralizing antibody titers in the pooled milk of the first 8 lactation days about 100-fold when compared with those in control cows (Table 1) .
MATERIALS AND METHODS
Very high neutralizing antibody titers were found in the colostral milk from the first two milkings of cows that were immunized with any of the four human rotavirus serotypes.
Thereafter, neutralizing antibody titers decreased rapidly but remained significantly higher than those in control cows for an extended period (Fig. 1) . This decrease in neutralizing milk antibodies with progressing lactation parallels the decrease of antirotavirus IgG, which is the major immunoglobulin of bovine colostrum and milk (16) from the pooled milk of the first 40 lactation days of control cows, we found a mean neutralization titer of 65 against human rotaviruses (Table 2 , MI concentrate 0), which is comparable to the neutralizing activity of pooled human breast milk (Table 2) . A fivefold higher neutralization titer was obtained when milk immunoglobulin concentrate was prepared from the first day colostrum of control cows ( Table  2 , MI concentrate A). Milk immunoglobulin concentrate prepared from the pooled milk of the first 40 lactation days of immunized cows showed a mean neutralization titer of 1,100 ( Table 2 , MI concentrate B), which was comparable to the neutralization activity of commercial human pooled immunoglobulins from blood serum ( Table 2) . Milk immunoglobulin concentrate isolated from the pooled milk of the first 10 lactation days of immunized cows gave a neutralization titer of 5,800 (Table 2 , MI concentrate C), which was 10-fold higher than the activity of human pooled immunoglobulins. For milk immunoglobulin concentrate B and C (Table 2) preparations, milk from cows immunized with each of the different human rotavirus serotypes was included in the pooled milk. However, milk from cows immunized either with a single human rotavirus strain ( (Fig. 2) .
A kinetic analysis of the neutralization process showed that 103 TCID50 of rotavirus SA11 were instantaneously neutralized by a 1:1,000 dilution of milk immunoglobulin concentrate C (100 ,ug of milk immunoglobulin concentrate per ml) and within 10 min by a 1:10,000 dilution (10 ,ug of milk immunoglobulin concentrate per ml), whereas corresponding dilutions of milk immunoglobulin concentrate from control cows neutralized the input virus only slowly and partially or not at all (Fig. 3) . DISCUSSION It has been shown that large amounts of human rotavirus neutralizing antibodies can be isolated from colostrum and transition milk of hyperimmunized cows.
For several reasons cows are ideal animals for the production of antirotavirus antibodies. Rotaviruses are common pathogens for cows (35) , and therefore, bovine blood serum and milk show appreciable natural neutralizing antibody titers against rotaviruses (1, 36) (Fig. 1 and Table 1 ). Bovine serum (29) and milk (38) It has been shown that either human pooled immunoglobulins or bovine milk antibodies from rotavirus-immunized cows could prevent rotavirus gastroenteritis when added to the food of infants (2, 10, 11) . Thus, milk immunoglobulin concentrate may offer an attractive means of prophylaxis of rotavirus gastroenteritis in infants at risk, e.g., nurseries for premature babies, day-care centers, hospitalized infants, and household contacts (9) . In industrialized countries, at least, a considerable proportion of rotavirus diarrhea treated in hospitals may be nosocomially acquired (8, 23, 32) .
It may even be beneficial to treat hospitalized infants suffering from acute rotavirus gastroenteritis with milk immunoglobulin concentrate because, as has been shown here, milk immunoglobulin concentrate neutralizes very high doses of infectious rotavirus. When given orally to patients infected with rotavirus, it may reduce the number of infectious rotavirus isolates that are excreted into the feces and thus also reduce the risk for surrounding patients. Indeed, for rotavirus gastroenteritis outbreaks, high secondary attack rates have been reported (12, 21, 22) . If a propagation of the infection process takes place along the intestine of patients infected with rotavirus, as has been hypothesized for calves (17) , milk immnunoglobulin concentrate might interfere with this propagation and thus also be directly beneficial for the patient infected with rotavirus. In fact, in a clinical test for the therapeutic use of milk immunoglobulin concentrate now under way, a shortening of virus excretion time was observed in milk immunoglobulin concentrate treated infants when compared with that in matched controls (Hilpert et al., in press).
